Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, producing significant effects on body weight and blood glucose
Our patient-centered approach puts your preferences and concerns at the forefront, ensuring a collaborative treatment experience
This creates a common certificate-of-analysis problem
*Correspondence: Mara Dolores Garca de Lucas, [email protected] Present address: Mara Dolores Garca de Lucas, Internal Medicine Department, Regional University Hospital, Mlaga, Spain Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
No data are available in the literature on the percentage of patients requiring insulin therapy at diagnosis